📜Tert-Butyl 2-(4-(2-(3,5-Dimethylphenylamino)-2-Oxoethyl)Phenoxy)-2-Methylpropanoate置于甲酸体系中,化学反应 0.13H,以89%的收率获得乙丙昔罗 参考文献:Trimethylaluminium Mediated Amide Bond Formation In A Continuous Flow Microreactor As Key To The Synthesis Of Rimonabant And Efaproxiral 标题:Trimethylaluminium Mediated Amide Bond Formation In A Continuous Flow Microreactor As Key To The Synthesis Of Rimonabant And Efaproxiral 摘要:在微反应器系统中,开发了一种安全,官能团耐受性强且高通量的三甲基铝介导的酰胺键形成反应版本;以利莫那班和依法罗西拉为例,展示了该方法的应用效果. Doi:10.1039/b719603B
专利号:US-2017283878-A1 优先权日:2015-12-11 标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers 发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING 权利人:ACADEMIA SINICA 摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.
专利号:US-2024287041-A1 优先权日:2021-05-20 标题 :Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms 发明人:BALOGLU ERKAN; AUSTAD BRIAN C; ROE DAVID G; KEDUC ANDREW; GOTTSCHLING STEPHEN EDMUND; HECKER EVAN 权利人:KARYOPHARM THERAPEUTICS INC 摘要:The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.
专利号:US-2022363662-A1 优先权日:2021-04-20 标题 :Compounds as lxr agonists 发明人:PUJALA BRAHMAM; SATHE BALAJI DASHRATH; DANODIA ABHINANDAN; GUPTA ASHU; SONI SANJEEV; KUMAR VIVEK; ANSARI AMANTULLAH; KHAN FARHA; SARKAR ARINDAM; PAYGHAN PAVAN V 权利人:INTEGRAL BIOSCIENCES PRIVATED LTD 摘要:The present invention generally discloses compounds having LXR (the liver X receptor) agonistic activity, to the use of such compounds in the treatment of various disorders such as proliferative disorders, Alzheimer's disease, inflammatory diseases, and diseases characterized by defects in cholesterol and lipid metabolism. Specifically, the present invention discloses compound of formula (IA) which exhibit LXR agonist activity, specifically to LXRβ. The invention also discloses method of synthesis of said compounds, method of using said compounds, pharmaceutical compositions comprising said compounds and method of using thereof.
专利号:AU-2022276509-A1 优先权日:2021-05-20 标题:Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
专利号:US-9994558-B2 优先权日:2013-09-20 标题 :Multicyclic compounds and methods of using same 发明人:BALOGLU ERKAN; SHACHAM SHARON; SENAPEDIS WILLIAM; MCCAULEY DILARA; LANDESMAN YOSEF; GOLAN GALI; KALID ORI; SHECHTER SHARON 权利人:KARYOPHARM THERAPEUTICS INC 摘要:The invention generally relates to compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders (e.g., PAK-mediated, for example, PAK4-mediated, diseases and disorders).
专利号:EP-3686190-A1 优先权日:2013-07-11 标 题 :Synthesis of therapeutically active compounds
1: Watanabe A, Poole DC, Kano Y. The effects of RSR13 on microvascular Po(2) kinetics and muscle contractile performance in the rat arterial ligation model of peripheral arterial disease. J Appl Physiol (1985). 2017 Oct 1;123(4):764-772. doi: 10.1152/japplphysiol.00257.2017. Epub 2017 Jun 15. doi: 10.1080/17474086.2017.1313699. Epub 2017 Apr 12. Review. doi: 10.1021/acs.biochem.5b01074. Epub 2015 Dec 3. 4: Görgens C, Guddat S, Schänzer W, Thevis M. Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes. Drug Test Anal. 2014 Nov-Dec;6(11-12):1102-7. doi: 10.1002/dta.1700. Epub 2014 Jul 28. doi: 10.1002/jms.3304. Review. doi: 10.1007/s11060-009-0058-3. Epub 2009 Dec 3. 8: Viani GA, Manta GB, Fonseca EC, De Fendi LI, Afonso SL, Stefano EJ. Whole brain radiotherapy with radiosensitizer for brain metastases. J Exp Clin Cancer Res. 2009 Jan 6;28:1. doi: 10.1186/1756-9966-28-1.
合成参考文献
参考文献:10.1152/ajpheart.1999.277.1.h290 摘要:Eichelbrönner O, Sielenkämper A, Ellis MDCG, Sibbald WJ, Chin-Yee IH. Effects of F I O 2 on hemodynamic responses and O2 transport during RSR13-induced reduction in P50. American Journal of Physiology-Heart and Circulatory Physiology. 1999 Jul 01;277(1):H290–8. doi: 10.1152/ajpheart.1999.277.1.h290. 参考文献:10.1152/ajpheart.00863.2001 摘要:Wainwright MS, Sheng H, Sato Y, Burkhard Mackensen G, Steffen RP, Pearlstein RD, Warner DS. Pharmacological correction of hypothermic P50shift does not alter outcome from focal cerebral ischemia in rats. American Journal of Physiology-Heart and Circulatory Physiology. 2002 May 01;282(5):H1863–70. doi: 10.1152/ajpheart.00863.2001. 参考文献:10.1517/13543784.13.5.543|10.1517/eoid.13.5.543.31790 摘要:Suh JH. Efaproxiral: a novel radiation sensitiser. Expert Opin Investig Drugs. 2004 May;13(5):543–50. doi: 10.1517/13543784.13.5.543. 参考文献:10.1007/bf03345588 摘要:Borrione P, Mastrone A, Salvo RA, Spaccamiglio A, Grasso L, Angeli A. Oxygen delivery enhancers: Past, present, and future. Journal of Endocrinological Investigation. 2008 Feb;31(2):185–92. doi: 10.1007/bf03345588. 参考文献:10.1200/jco.1999.17.8.2593 摘要:Kleinberg L, Grossman SA, Piantadosi S, Pearlman J, Engelhard H, Lesser G, Ruffer J, Gerber M. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. J Clin Oncol. 1999 Aug;17(8):2593–603. doi: 10.1200/jco.1999.17.8.2593.